Page 39 - Oncology Coder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology coder. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Coder Today - Breaking & Trending Today

Tessellate Bio draws $8.4M in seed to try alternative synthetic lethality approach

With an initial €8 million (US$8.4 million) in seed funding in the bank, Tessellate Bio has emerged from stealth to tackle cancers that rely on the less well explored synthetic lethality mechanism of alternative lengthening of telomeres. ....

Tessellate Bio , Synthetic Lethality ,

MU Health Care initiates first treatment of MU Research Reactor-produced cancer drug

Pluvicto includes lutetium-177 (Lu-177), a radioisotope only produced in the U.S at the MU Research Reactor. ....

United States , Gregory Biedermann , Mu Research Reactor , Mu Health Care , Drug Administration , Health Care , Veterinary Science ,

Carrier status of an actionable gene is associated with reduced life span in large Icelandic study

1. In this cross-sectional study, having carrier status of actionable genes identified by the American College of Medical Genetics and Genomics (ACMG) was associated with reduced life span compared to non-carrier status. 2. Having carrier status for an actionable cancer gene was associated with a shorter life span by an average of three years compared ....

American College Of Medical Genetics , Minute Medicine Inc , American College , Medical Genetics , Rating Level , Confidence Interval , Actionable Genes , Carrier Status , Public Health ,

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs. ....

Michael Mauro , Memorial Sloan Kettering Cancer Center , Myeloproliferative Neoplasms Program , Ash Annual Meeting And Exposition ,

Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study

In this observational study, Yichen Zhang and colleagues explore how comparator arms are used in randomized oncology trials registered in China. ....

Eteläuomen Läi , United States , Anitak Wagner , Huseyin Naci , National Medical Products Administration , Chinese Society Of Clinical Oncology , Drug Administration , University Health Science Center , Harvard Medical School , London School Of Economics , Oriented Oncology Drug Research , National Natural Science Foundation Of China , Oncologic Drugs Advisory Committee , China Center , National Comprehensive Cancer Network , China National Knowledge Infrastructure , Research On Equitable Access , Department Of Population Medicine , Harvard Pilgrim Health Care Institute , National Clinical Trial , Department Of Health , China Medicinal Product Administration Law , Us National Library Of Medicine , Drug Evaluation , Clinical Value Oriented Oncology Drug Research , Creative Commons Attribution License ,